Drug Profile
Cerlapirdine
Alternative Names: Cerlapirdine hydrochloride; PF-05212365; PF-5212365; SAM-531; WAY-262531Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Antidementias
- Mechanism of Action Serotonin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Schizophrenia
Most Recent Events
- 01 Apr 2011 Pfizer completes enrolment in its phase II trial for Alzheimer's disease in USA, Europe, Asia, Latin America, New Zealand and South Africa (NCT00895895)
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 05 Oct 2006 Phase-I clinical trials in Alzheimer's disease in USA (PO)